AI > Humans soon?

JOIN ME LIVE SATURDAY @ 10am PT / 1pm ET ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [JOIN OUR LIVE SESSION! REGISTER NOW!]( Hello investor Biotech is one of the most difficult fields to be in. Pharma companies will spend billions of dollars to research just to discover the next “hit” drug. But it could change soon. Artificial intelligence allows people to test potential drug ideas for 10x cheaper. LabGenius is doing it now by using AI to engineer new medical antibodies. However, there are literally millions of ways to manipulate molecules to create a new product that will prevent viruses from spreading. - “If you want to create a new therapeutic antibody, somewhere in this infinite space of potential molecules sits the molecule you want to find,” says James Field, the founder and CEO of LabGenius. With AI, LabGenius is able to tell the machine what the goal is, and it will work hard to find the right combination to achieve it. - “The only input you give the system as a human is, here’s an example of a healthy cell, here’s an example of a diseased cell,” says Field. “And then you let the system explore the different [antibody] designs that can differentiate between them.” As a result, it was able to uncover the first batch of a potential treatment in just six weeks… …purely from machine learning models. That’s the power of AI, and it is going to transform Wall Street. Hedge funds are spending a fortune to develop AI technologies, but retail investors are still investing like they are in the “Stone Age.” They often use Yahoo Finance or Webull which have inferior technologies. Surely, you’re aware that the boom in technology has widened the wealth gap in society. Artificial intelligence will likely accelerate the gap in the investing world… …unless someone does something about it. TradeAlgo is stepping up with our new project to build the AI platform that could enable retail investors to leverage AI technology like Bridgewater Associates has been using. This AI platform could theoretically be like having a super-intelligent trading assistant to help retail investors make smart trading decisions. How can you seize this opportunity? Join us this Saturday at 10am PT to learn how to own Pre-IPO shares in TradeAlgo… while it is extremely early. We expect the shares to run out very quickly. So, click the button below to register: [JOIN US LIVE SATURDAY @ 10am PT / 1pm ET]( * We will attempt to trade in a paper-trading account – not with a real portfolio. No returns are guaranteed. No longer want to receive these emails? [Unsubscribe](. Trader Algo 401 Park Ave S New York, NY 10016, NY 10016